新型硬皮病临床试验联盟活动指数(SCTC-AI)的研制与初步验证
硬皮病临床试验联盟(SCTC)活动指数工作组采用共识方法定义疾病活动性,通过文献回顾、专家共识和德尔菲调查生成并缩减条目,在澳大利亚硬皮病队列研究(n=1,254)中用时依Cox回归对条目加权,最终形成24条目、最高140分的SCTC-AI,并在加拿大硬皮病研究组1,103例参与者中外部验证,显示疾病活动评分与生存呈分级关系(P<0.01)。
要点
- SCTC-AI共24个条目,最高可能评分为140分。
- 外部验证显示疾病活动评分与生存呈分级关系(P<0.01)。
- 作者指出需进一步工作以充分验证和确认SCTC-AI的结构效度与区分效度。
核心结论
- 作者提出一种量化系统性硬化症疾病活动负担的新工具SCTC-AI,采用严谨的共识流程结合数据驱动方法研制,具有表面效度、内容效度和标准效度。
- 作者指出需进一步工作以充分验证和确认SCTC-AI的结构效度与区分效度。
研究设计与样本
- 硬皮病临床试验联盟(SCTC)活动指数工作组采用共识方法学研制疾病活动性测量工具SCTC-AI。
- 通过文献回顾和专家共识生成暂定SCTC-AI条目,并经德尔菲调查缩减。
- 利用澳大利亚硬皮病队列研究(ASCS)(n=1,254)的时间依赖Cox比例风险回归分析,以发病和死亡的联合终点对暂定条目进行加权。
- 使用加拿大硬皮病研究组1,103例参与者所收集数据进行SCTC-AI的外部验证。
主要发现
- 系统性硬化症疾病活动性经共识方法学定义为「随时间推移和/或有效治疗可逆转或可被阻止的疾病方面」。
- 共生成141个暂定SCTC-AI条目,经三轮德尔菲调查及针对死亡和生活质量指标的统计缩减与加权,最终形成24条目指数,最高可能评分为140分。
- 外部队列生存分析显示疾病活动评分与生存之间呈分级关系(P < 0.01)。
关键数值与推荐
- SCTC-AI最终为24条目指数,最高可能评分为140分。
- 外部验证队列中疾病活动评分与生存呈分级关系(P < 0.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出需进一步工作以充分验证和确认SCTC-AI的结构效度与区分效度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Accurate measurement of disease activity in systemic sclerosis (SSc) remains a significant clinical challenge. The Scleroderma Clinical Trials Consortium (SCTC) convened an Activity Index (AI) Working Group (WG) to develop a novel measure of disease activity (SCTC-AI). METHODS: Using consensus methodology, we developed a conceptual definition of disease activity. Literature review and expert consensus generated provisional SCTC-AI items, which were reduced by Delphi survey. Provisional items were weighted against a combined endpoint of morbidity and mortality, using time-dependent Cox proportional hazards regression analysis of the Australian Scleroderma Cohort Study (ASCS) (n = 1,254). External validation of the SCTC-AI was performed using data collected from 1,103 Canadian Scleroderma Research Group Study participants. RESULTS: Disease activity in SSc was defined using consensus methodology as "aspects of disease that are reversible, or can be arrested, with time and, or effective therapy." One-hundred and forty-one provisional SCTC-AI items were generated and reduced using three rounds of Delphi survey and statistical reduction and weighting, against mortality and quality of life measures, yielding a final 24-item index with a maximum possible score of 140. Survival analysis in an external cohort showed a graded relationship between disease activity scores and survival (P < 0.01). CONCLUSION: We present a novel instrument to quantify the burden of disease activity in SSc. We have employed a rigorous consensus-based process in combination with data-driven methods to develop an instrument that has face, content, and criterion validity. Further work is required to fully validate and confirm the construct and discriminative validity of the SCTC-AI.
引用
- Ross L, Hansen D, Proudman S, et al. Development and Initial Validation of the Novel Scleroderma Clinical Trials Consortium Activity Index. Arthritis Rheumatol. 2024. PMID: 38937146. doi:10.1002/art.42939
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。